IGF-1 levels inversely associated with T2DM risk in dose-dependent manner, but only among those with birth weight \u22652.5 kg<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 2, 2021 (HealthDay News) — Birth weight modifies the association between adulthood levels of circulating insulin-like growth factor-1 (IGF-1) and development of type 2 diabetes (T2D), with an inverse association seen among those with a birth weight \u00e2\u0089\u00a52.5 kg, according to a study published online March 1 in BMJ Open Diabetes Research & Care<\/em>.<\/p>\n Tingting Geng, from the National University of Singapore, and colleagues examined the interaction between circulating IGF-1 and birth weight in relation to T2D in a cohort of 181,090 adults, aged 39 to 70 years, in the U.K. Biobank Study. A chemiluminescent immunoassay method was used to determine serum IGF-1 levels.<\/p>\n During an average follow-up of 9.9 years, the researchers identified 3,299 incident T2D cases. IGF-1 levels were inversely associated with T2D risk in a dose-dependent manner among participants with a birth weight \u00e2\u0089\u00a52.5 kg. In contrast, no significant association was seen among those with a birth weight <2.5 kg. There was no interaction noted for the genetic risk score of birth weight with IGF-1 levels in relation to T2D risk.<\/p>\n “Our data indicate that the relation between adulthood IGF-1 and T2D is significantly modified by birth weight,” the authors write. “Our findings highlight the importance of early-life risk factors in the development of the lifecourse prevention strategies targeting on IGF-1 and T2D.”<\/p>\n